Yentli Soto Albrecht

Yentli is an MD-PhD student and C9orf72 expansion carrier that pivoted to neurodegeneration research after her father’s death from rapidly progressive familial ALS in 2024. Her previous doctoral training in viral pathogenesis and mitochondrial biology, covering topics like: protein aggregation, cellular dysfunction, metabolic dysregulation, translates directly to the mechanisms underlying neurodegeneration. As a genetic carrier, scientist, and physician-in-training herself, she approaches this work from all three sides simultaneously. Yentli currently manages eleven collaborative C9orf72 projects across eight countries while completing her medical training. One of these projects received the 2025 ALS Network Research Innovation Grant ($150,000), another has been accepted into Stage 1 of the Longitude Prize on ALS, and the most recent is CureC9, a program within EverythingALS dedicated to curing C9orf72 disease. Yentli is committed to translating biological discoveries into treatments that matter for the patients and families facing these diseases, starting with her own.